drugset / Trial / NCT00766857

Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

NCT00766857

Phase 4 Completed 27 enrolled Amsterdam UMC, location VUmc
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if exenatide will improve global cardiac function in patients with type 2 diabetes mellitus and congestive heart failure, by favorable effects on cardiac metabolism leading to improvement of cardiac efficiency.

Timeline

Start
2009-05
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug
Comparator insulin glargine Protein / enzyme biologic 10 iu